XML 28 R18.htm IDEA: XBRL DOCUMENT v3.22.2.2
Taxes on Income
9 Months Ended
Sep. 30, 2022
Income Tax Disclosure [Abstract]  
Taxes on Income Taxes on Income
The effective income tax rates were 19.6% and 17.1% for the three months ended September 30, 2022 and 2021, respectively, and 20.0% and 11.2% for the nine months ended September 30, 2022 and 2021, respectively. These effective income tax rates reflect the beneficial impact of foreign earnings, offset by the impact of U.S. inclusions under the Global Intangible Low-Taxed Income regime. The effective income tax rate for the first nine months of 2021 reflects the beneficial impact of foreign earnings, a $70 million tax benefit relating to a portion of the non-U.S. step-up of tax basis as well as the income tax benefit recognized in connection with the conclusion of the Internal Revenue Service (IRS) examination of Merck’s 2015-2016 U.S. federal income tax returns. As a result, the Company reflected an allocation from Merck of $18 million representing the Company's portion of the payment made to the IRS in the Condensed Consolidated Financial Statements. The Company's portion of reserves for unrecognized tax benefits for the years under examination exceeded the allocated adjustments relating to this examination period and therefore the Company included a $29 million net tax benefit also included in the nine months ended September 30, 2021. This net benefit reflects reductions in reserves for unrecognized tax benefits and other related liabilities for tax positions relating to the years that were under examination.

On August 16, 2022, the U.S. enacted the Inflation Reduction Act of 2022. Provisions of the bill that relate to tax include the minimum tax on book income, a 1% excise tax on stock buybacks and certain tax incentives to promote clean energy. There are no impacts of the legislation to the third quarter 2022 results. The Company is currently assessing future impacts of this recently enacted legislation.